600 related articles for article (PubMed ID: 8120958)
1. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
2. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
Lindsey KR; Rosenberg SA; Sherry RM
J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637
[TBL] [Abstract][Full Text] [Related]
3. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; AramendÃa JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
4. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
Rosenberg SA; Yang JC; White DE; Steinberg SM
Ann Surg; 1998 Sep; 228(3):307-19. PubMed ID: 9742914
[TBL] [Abstract][Full Text] [Related]
5. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.
Guleria AS; Yang JC; Topalian SL; Weber JS; Parkinson DR; MacFarlane MP; White RL; Steinberg SM; White DE; Einhorn JH
J Clin Oncol; 1994 Dec; 12(12):2714-22. PubMed ID: 7989949
[TBL] [Abstract][Full Text] [Related]
6. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
Yang JC; Topalian SL; Parkinson D; Schwartzentruber DJ; Weber JS; Ettinghausen SE; White DE; Steinberg SM; Cole DJ; Kim HI
J Clin Oncol; 1994 Aug; 12(8):1572-6. PubMed ID: 8040669
[TBL] [Abstract][Full Text] [Related]
7. Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.
Sosman JA; Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; O'Boyle K; Fisher RI; Boldt DH; Doroshow J
J Clin Oncol; 1993 Aug; 11(8):1496-505. PubMed ID: 8336188
[TBL] [Abstract][Full Text] [Related]
8. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
[TBL] [Abstract][Full Text] [Related]
9. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma.
MacFarlane MP; Yang JC; Guleria AS; White RL; Seipp CA; Einhorn JH; White DE; Rosenberg SA
Cancer; 1995 Feb; 75(4):1030-7. PubMed ID: 7842405
[TBL] [Abstract][Full Text] [Related]
10. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
11. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
Marincola FM; White DE; Wise AP; Rosenberg SA
J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
[TBL] [Abstract][Full Text] [Related]
13. Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma.
Karp SE
J Immunother; 1998 Jan; 21(1):56-61. PubMed ID: 9456437
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
[TBL] [Abstract][Full Text] [Related]
15. Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW; Kurt RA; Baher AG; Denman S; Justice L; Doran T; Gilbert M; Alvord WG; Urba WJ
J Immunother; 2003; 26(2):130-8. PubMed ID: 12616104
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
[TBL] [Abstract][Full Text] [Related]
17. Decreased tolerance to interleukin-2 with repeated courses of therapy in patients with metastatic melanoma or renal cell cancer.
Marroquin CE; White DE; Steinberg SM; Rosenberg SA; Schwartzentruber DJ
J Immunother; 2000; 23(3):387-92. PubMed ID: 10838668
[TBL] [Abstract][Full Text] [Related]
18. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
Yang JC; Rosenberg SA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400
[TBL] [Abstract][Full Text] [Related]
19. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
Atkins MB; Kunkel L; Sznol M; Rosenberg SA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S11-4. PubMed ID: 10685652
[TBL] [Abstract][Full Text] [Related]
20. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]